THERAVANCE BIOPHARMA INC's ticker is TBPH and the CUSIP is G8807B106. A total of 93 filers reported holding THERAVANCE BIOPHARMA INC in Q1 2018. The put-call ratio across all filers is 0.14 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2021 | $7,252,000 | +49.3% | 656,296 | 0.0% | 0.23% | +49.4% |
| Q3 2021 | $4,857,000 | -49.0% | 656,296 | 0.0% | 0.16% | -49.7% |
| Q2 2021 | $9,529,000 | +2.3% | 656,296 | +43.8% | 0.31% | -3.1% |
| Q1 2021 | $9,313,000 | +14.9% | 456,296 | 0.0% | 0.32% | +12.3% |
| Q4 2020 | $8,108,000 | +83.7% | 456,296 | +52.9% | 0.28% | +72.7% |
| Q3 2020 | $4,413,000 | -8.1% | 298,470 | +30.4% | 0.16% | -9.8% |
| Q2 2020 | $4,803,000 | -9.2% | 228,836 | 0.0% | 0.18% | -23.4% |
| Q1 2020 | $5,288,000 | +73.5% | 228,836 | +94.4% | 0.24% | +107.8% |
| Q4 2019 | $3,048,000 | +239.4% | 117,725 | +155.4% | 0.12% | +194.9% |
| Q3 2019 | $898,000 | +240.2% | 46,101 | +470.3% | 0.04% | +290.0% |
| Q3 2018 | $264,000 | +44.3% | 8,083 | 0.0% | 0.01% | +42.9% |
| Q2 2018 | $183,000 | -6.6% | 8,083 | 0.0% | 0.01% | -12.5% |
| Q1 2018 | $196,000 | – | 8,083 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Chescapmanager LLC | 1,134,718 | $23,160,000 | 2.47% |
| Baupost Group | 8,735,168 | $178,285,000 | 1.42% |
| Orbimed Advisors | 6,219,110 | $126,932,000 | 1.19% |
| CM Management, LLC | 50,000 | $1,021,000 | 0.76% |
| Tekla Capital Management LLC | 456,296 | $9,313,000 | 0.32% |
| Rock Springs Capital Management LP | 682,600 | $13,932,000 | 0.30% |
| Virtus ETF Advisers LLC | 32,871 | $671,000 | 0.28% |
| Cormorant Asset Management, LP | 550,000 | $11,226,000 | 0.25% |
| DAFNA Capital Management LLC | 41,165 | $840,000 | 0.20% |
| PEREGRINE CAPITAL MANAGEMENT LLC | 484,206 | $9,883,000 | 0.18% |